Clarkston Consulting
Skip to content

Life Sciences Expert Janel Firestein Speaks to Catalent Acquisition

February 13, 2024  | Clarkston Partner and Life Sciences Industry Lead Janel Firestein shared insight with Chemistry World on the recent Novo Holdings deal. Novo Holdings, the parent company to Novo Nordisk, announced a deal to acquire Catalent, a leading global CDMO known for its broad end-to-end CDMO capabilities. The deal, valuing Catalent at $16.5bn, is designed to help improve supply challenges that have been holding back the growth of their blockbuster GLP-1 drug semaglutide, more well-known by brand names Ozempic and Wegovy. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a standalone CDMO with a diversified set of customers. Speaking from her recent publication on the topic (What Does the Catalent Acquisition by Novo Holdings Mean for the Biopharma Industry?), see her quote below, and read the full article here

Novo Holdings to Buy Contract Manufacturer Catalent for $16.5 Billion

“By purchasing Catalent, this allows Novo Nordisk to meet demand by controlling manufacturing and really gaining more power over its supply chain,” says Janel Firestein, life sciences lead at Clarkson Consulting. “This is one of the most interesting deals in a while and came out of the blue. There’s lots of benefits [for Novo Nordisk].”

 Read the Full Article Here